(NASDAQ: ANAB) Anaptysbio's forecast annual revenue growth rate of 6.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.21%.
Anaptysbio's revenue in 2026 is $232,388,000.On average, 13 Wall Street analysts forecast ANAB's revenue for 2026 to be $4,493,761,287, with the lowest ANAB revenue forecast at $3,176,945,471, and the highest ANAB revenue forecast at $5,839,386,995. On average, 13 Wall Street analysts forecast ANAB's revenue for 2027 to be $6,164,735,080, with the lowest ANAB revenue forecast at $4,494,634,314, and the highest ANAB revenue forecast at $7,638,986,775.
In 2028, ANAB is forecast to generate $8,251,560,762 in revenue, with the lowest revenue forecast at $6,510,453,795 and the highest revenue forecast at $11,301,917,310.